T-cell Lymphoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte ™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix intends to seek guidance from the FDA on how to further advance HyBryte™ towards potential approval PRINCETON, N.J., Feb. 14, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 14, 2023 Category: Pharmaceuticals Source Type: clinical trials

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
Condition:   Extranodal NK/T-cell Lymphoma Interventions:   Biological: Sugemalimab;   Drug: Placebo;   Drug: Pegaspargase;   Drug: Gemcitabine;   Drug: Oxaliplatin Sponsor:   CStone Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2023 Category: Research Source Type: clinical trials

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Condition:   Lymphoma Interventions:   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone Sponsor:   Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials